Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Meiji Rolls Out COVID Jab Kostaive in Japan
Meiji Seika Pharma on September 30 launched its self-amplifying mRNA COVID-19 vaccine Kostaive in Japan, which will be used under the government’s inoculation program for the 2024/2025 fall-winter season. A JN.1-targeted version of Kostaive that hit the market was approved…
To read the full story
Related Article
- COVID Shot Kostaive Lands EU Approval, 1st Nod Outside Japan
February 19, 2025
- Domestic Sites Approved for Meiji’s COVID Vaccine Kostaive
February 4, 2025
- Japan Approves Meiji’s JN.1-Directed COVID-19 Vaccine
September 13, 2024
BUSINESS
- Santen Snags China Rights to 5 Glaucoma Drugs from AbbVie
April 20, 2026
- AbbVie Launches Aquipta Migraine Drug in Japan
April 20, 2026
- Fronteo, Astellas Partner on AI-Driven Drug Target Discovery
April 20, 2026
- Towa to Outsource 1.5 Billion Tablets to Adragos by 2033
April 20, 2026
- Lilly’s Omvoh 200 mg SC Wins Japan Nod for UC Maintenance Use
April 17, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…